Cell 1994,76(6):1025–1037.PubMedCrossRef 16. Puthalakath H, Villunger A, O’Reilly LA, Beaumont JG, Coultas Tubastatin A concentration L, Cheney RE, Huang DC, Strasser A: Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis.
Science 2001,293(5536):1829–1832.PubMedCrossRef 17. Zhang Y, Adachi M, Kawamura R, Zou HC, Imai K, Hareyama M, Shinomura Y: Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation. Apoptosis 2006,11(8):1349–1357.PubMedCrossRef 18. Fu X, Yucer N, Liu S, Li M, Yi P, Mu JJ, Yang T, Chu J, Jung SY, O’Malley BW, et al.: RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc Natl Acad Sci U S A 2010,107(10):4579–4584.PubMedCrossRef 19. Zhou X, Suzuki H, Shimada Y, Imamura M, Yin J, Selleck CX-6258 Jiang HY, Tarmin L, Abraham JM, Meltzer S: Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes Chromosomes Cancer 1995,13(4):285–290.PubMedCrossRef 20. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994,371(6494):257–261.PubMedCrossRef 21. Xiang Y, Lin G, Zhang
Q, Tan Y, Lu G: Knocking down Wnt9a mRNA levels increases cellular proliferation. Mol Biol Rep 2008,35(2):73–79.PubMedCrossRef 22. Zhang Y, Chen FQ, Sun YH, Zhou SY, Li TY, Chen R: Effects of DNMT1 silencing on malignant 4SC-202 clinical trial phenotype and methylated gene expression in cervical cancer cells. J Exp Clin Cancer Res 2011, 30:98.PubMedCrossRef 23. An HJ, Lee H, Paik SG: Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway. Mol
Cells 2011,31(6):579–583.PubMedCrossRef 24. Murai M, Toyota M, Suzuki H, Satoh A, Sasaki Y, Akino K, Ueno M, Takahashi F, Kusano M, Mita H, et al.: Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 2005,11(3):1021–1027.PubMed 25. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP: Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 2006,66(10):5077–5084.PubMedCrossRef Competing interests The authors declare that the y have oxyclozanide no competing interests. Authors’ contributions MZH carried out animal experiment, histological analysis, molecular genetic studies, statistical analyses and drafted the manuscript. YY contributed to animal experiment and TUNEL staining. ZL participated in histological analysis and statistical analyses. LKY conceived of the study and designed the topic. All authors read and approved the final manuscript.”
“Introduction Chemotherapy agents have a low therapeutic index thus affecting also normal cells and not only cancer counterparts.